These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32946600)

  • 1. Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched Analysis.
    Deneau MR; Mack C; Mogul D; Perito ER; Valentino PL; Amir AZ; DiGuglielmo M; Draijer LG; El-Matary W; Furuya KN; Gupta N; Hochberg JT; Horslen S; Jensen MK; Jonas MM; Kerkar N; Koot BGP; Laborda TJ; Lee CK; Loomes KM; Martinez M; Miethke A; Miloh T; Mohammad S; Ovchinsky N; Rao G; Ricciuto A; Sathya P; Schwarz KB; Shah U; Singh R; Vitola B; Zizzo A; Guthery SL
    Hepatology; 2021 Mar; 73(3):1061-1073. PubMed ID: 32946600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Lindor KD; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; Mooney J; Sargeant C; Braaten J; Bernard T; King D; Miceli E; Schmoll J; Hoskin T; Thapa P; Enders F
    Hepatology; 2009 Sep; 50(3):808-14. PubMed ID: 19585548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course.
    Deneau M; Perito E; Ricciuto A; Gupta N; Kamath BM; Palle S; Vitola B; Smolka V; Ferrari F; Amir AZ; Miloh T; Papadopoulou A; Mohan P; Mack C; Kolho KL; Iorio R; El-Matary W; Venkat V; Chan A; Saubermann L; Valentino PL; Shah U; Miethke A; Lin H; Jensen MK
    J Pediatr; 2019 Jun; 209():92-96.e1. PubMed ID: 30878206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
    Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P
    Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study.
    Rahimpour S; Nasiri-Toosi M; Khalili H; Ebrahimi-Daryani N; Nouri-Taromlou MK; Azizi Z
    J Gastrointestin Liver Dis; 2016 Dec; 25(4):457-464. PubMed ID: 27981301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
    Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW
    Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
    Harnois DM; Angulo P; Jorgensen RA; Larusso NF; Lindor KD
    Am J Gastroenterol; 2001 May; 96(5):1558-62. PubMed ID: 11374699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis.
    Arizumi T; Tazuma S; Isayama H; Nakazawa T; Tsuyuguchi T; Takikawa H; Tanaka A;
    J Gastroenterol; 2022 Nov; 57(11):902-912. PubMed ID: 36068441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?
    van Milligen de Wit AW; Kuiper H; Camoglio L; van Bracht J; Jones EA; Tytgat GN; van Deventer SJ
    Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):129-36. PubMed ID: 10102223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children.
    Gilger MA; Gann ME; Opekun AR; Gleason WA
    J Pediatr Gastroenterol Nutr; 2000 Aug; 31(2):136-41. PubMed ID: 10941964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
    Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
    J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.
    Sinakos E; Marschall HU; Kowdley KV; Befeler A; Keach J; Lindor K
    Hepatology; 2010 Jul; 52(1):197-203. PubMed ID: 20564380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.
    Imam MH; Sinakos E; Gossard AA; Kowdley KV; Luketic VA; Edwyn Harrison M; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; DeCook AC; Enders F; Lindor KD
    Aliment Pharmacol Ther; 2011 Nov; 34(10):1185-92. PubMed ID: 21957881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
    van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
    J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
    Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
    Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.
    Cullen SN; Rust C; Fleming K; Edwards C; Beuers U; Chapman RW
    J Hepatol; 2008 May; 48(5):792-800. PubMed ID: 18314215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Smith T; Befeler AS
    Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
    Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
    Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
    Eaton JE; Silveira MG; Pardi DS; Sinakos E; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Lindor KD
    Am J Gastroenterol; 2011 Sep; 106(9):1638-45. PubMed ID: 21556038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
    Charatcharoenwitthaya P; Angulo P; Enders FB; Lindor KD
    Hepatology; 2008 Jan; 47(1):133-42. PubMed ID: 17992695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.